ALK-Abelló stock

ALK.B · Nasdaq Copenhagen · DKK

Compare ALK-Abelló
kr 246.00Change from previous close: −2.84%Absolute change: −kr 7.20

Close · November 17, 2026

Price history

+5.93% over the period

1 year: from kr 236.00 (November 17, 2025) to kr 250.00 (November 17, 2026), +5.93%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026kr 250.00
October 30, 2026kr 248.00
September 30, 2026kr 198.40
August 31, 2026kr 208.80
July 31, 2026kr 222.00
June 30, 2026kr 244.20
May 29, 2026kr 268.00
April 30, 2026kr 238.40
March 31, 2026kr 202.20
February 27, 2026kr 220.40
January 30, 2026kr 207.60
December 30, 2025kr 228.60
November 28, 2025kr 230.80
November 17, 2025kr 236.00

At a glance

  • The company

    Develops allergy immunotherapy products, adrenaline treatments, and allergen extracts for respiratory, food, and anaphylaxis allergies across multiple regions

  • Latest results

    Quarter to June 30, 2026 · EPS kr 1.50 (estimate kr 1.60)

TickerLandia's take on ALK-Abelló

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 191.80
52-wk highkr 271.40

−9.36% from the 52-week high

Analysts · 6 analysts

Average targetkr 289.67+17.75% vs. price

Buy 6 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: ALK-Abelló

Compared with similar companies: very high earnings stability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

ALK-Abelló is priced as in the past and in line with similar companies

On the latest fiscal year's earnings (2025), ALK-Abelló's P/E today is 46.3, in line with the median of its last 6 fiscal years (44.6; between 33.8 and 173.2 from 2016 to 2025). ALK-Abelló's P/E (trailing 12 months): 40.7, in line with the median of a group of 9 similar companies (40.7).

P/E compared with its history

Compared with 9 similar companies

ALK-Abelló's metrics compared with similar companies
MetricALK-AbellóPosition in the groupBand
P/E (trailing 12 months)40.7Middle
Forward P/E33.6Middle
Operating margin26.9%Middle
ROE21.2%High
Debt/equity0.06High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: ALK-Abelló. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 1.8B

Latest quarter · Q2 2026

Net income

kr 339M

Latest quarter · Q2 2026

Quarterly net margin

18.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
kr 55.04B
P/E
40.7
EPS
kr 6.10
Volume
97.07K
Daily trading
€5.79M
Dividend yield
0.65%
Last ex-dividend on March 17, 2026

How ALK-Abelló is changing

All results
  • Revenue grew 12.6% a year on average over the last 5 years

  • Operating margin rose from 10.5% to 26.4%

  • Profits turn into cash: free cash flow equal to 114% of net income

Returns

ALK-Abelló returns with dividends

kr 1,000 invested in ALK-Abelló 5 years ago, on November 17, 2021, would be worth kr 1,585 today with dividends reinvested: +58.51% in total, +9.65% per year. On price alone it would be kr 1,573 (+57.33%).

PeriodALK-Abellókr 1,000 becomes
1 month+5.49%kr 1,055
6 months−2.69%kr 973
Year to date+9.36%kr 1,094
1 year+6.73%kr 1,067
3 years+165.83%kr 2,658
5 years+58.51%kr 1,585
10 years+457.12%kr 5,571

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

ALK-Abelló: technical analysis

ALK-Abelló shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 9.0% below its all-time closing high (kr 270.40, June 12, 2026).

Trend
No clear trend
RSI (14 sessions)
58
Between 30 and 70
vs 200-session average
+7.87%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

    since November 13, 2026

  • Trading on November 17, 2026 was 2.4 times the 20-session average.

Support and resistance

Price areas where ALK-Abelló has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistancekr 271.20+10.24%2 touches, last on June 12, 2026
  2. Last pricekr 246.00
  3. Supportkr 236.47−3.88%3 touches, last on October 8, 2026
  4. Supportkr 228.80−6.99%4 touches, last on August 20, 2026
  5. Supportkr 223.60−9.11%2 touches, last on January 7, 2026

Volatility and risk

Volatility (60 sessions, annualised)
25.6%
Largest fall in the last year
−28.88%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

ALK-Abelló: seasonality

Average monthly price change over 27 years

+4.1%Jan−1.6%Feb+0.9%Mar+3.8%Apr+6.1%May−1.4%Jun−0.2%Jul+0.5%Aug+0.4%Sep−0.7%Oct+4.2%Nov+0.4%Dec

Over the last 27 years, the strongest month for ALK-Abelló has been May: +6.10% on average, positive in 18 years out of 27. The weakest has been February: −1.58% on average, positive in 13 years out of 26. November, the current month, has been positive in 14 years out of 26 (+4.17% on average).

Show chart data
MonthAverageMedianPositive years
January+4.15%+5.41%19 of 26
February−1.58%−0.56%13 of 26
March+0.87%−1.51%12 of 26
April+3.79%+3.89%18 of 27
May+6.10%+3.29%18 of 27
June−1.36%−0.82%11 of 27
July−0.23%+0.51%14 of 27
August+0.47%−0.94%12 of 27
September+0.38%−0.57%13 of 27
October−0.67%−0.37%13 of 27
November+4.17%+1.32%14 of 26
December+0.37%−0.56%12 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

ALK-Abelló and its competitors

GRAZAX, ACARIZAX, ODACTRA and RAGWITEK are among the allergy immunotherapy tablets that ALK-Abelló offers for grass pollen, house dust mite and ragweed allergies, while its adrenaline autoinjectors and nasal sprays are used for emergency treatment of anaphylaxis. The portfolio also includes vaccines, injections and sublingual drops for respiratory allergies, a biologic for food allergies called ALK 014, the klarify.me patient engagement platform and allergen extracts used in diagnosis.

Headquarters
Horsholm, Denmark
Employees
2,773
Founded
1923
Chief executive
Peter Halling
ALK-Abelló and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ALK-AbellóALK.B$8.09B26.9%40.7−2.69%
ABIVAXABVX$7.61B-6,270.4%—−23.78%
Bachem HoldingBANB$6.92B21.8%39.2+2.26%
Financière de TubizeTUB$11.78B0.0%109.0+19.01%
CamurusCAMX$4.36B37.4%58.5+43.18%
BioArcticBIOA.B$2.72B19.6%262.7−6.04%

Same industry or related industries, similar size. Compare ALK-Abelló with its competitors · Full profile